全文获取类型
收费全文 | 4726篇 |
免费 | 203篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 80篇 |
妇产科学 | 96篇 |
基础医学 | 701篇 |
口腔科学 | 69篇 |
临床医学 | 289篇 |
内科学 | 1208篇 |
皮肤病学 | 73篇 |
神经病学 | 234篇 |
特种医学 | 207篇 |
外科学 | 1014篇 |
综合类 | 26篇 |
预防医学 | 93篇 |
眼科学 | 51篇 |
药学 | 292篇 |
中国医学 | 4篇 |
肿瘤学 | 481篇 |
出版年
2023年 | 17篇 |
2022年 | 50篇 |
2021年 | 67篇 |
2020年 | 41篇 |
2019年 | 52篇 |
2018年 | 77篇 |
2017年 | 59篇 |
2016年 | 97篇 |
2015年 | 96篇 |
2014年 | 141篇 |
2013年 | 169篇 |
2012年 | 261篇 |
2011年 | 283篇 |
2010年 | 164篇 |
2009年 | 171篇 |
2008年 | 262篇 |
2007年 | 302篇 |
2006年 | 327篇 |
2005年 | 363篇 |
2004年 | 339篇 |
2003年 | 350篇 |
2002年 | 335篇 |
2001年 | 51篇 |
2000年 | 53篇 |
1999年 | 66篇 |
1998年 | 65篇 |
1997年 | 69篇 |
1996年 | 44篇 |
1995年 | 53篇 |
1994年 | 48篇 |
1993年 | 53篇 |
1992年 | 32篇 |
1991年 | 33篇 |
1990年 | 27篇 |
1989年 | 37篇 |
1988年 | 17篇 |
1987年 | 30篇 |
1986年 | 31篇 |
1985年 | 36篇 |
1984年 | 28篇 |
1983年 | 24篇 |
1982年 | 25篇 |
1981年 | 21篇 |
1980年 | 15篇 |
1979年 | 14篇 |
1978年 | 11篇 |
1977年 | 8篇 |
1974年 | 7篇 |
1969年 | 6篇 |
1967年 | 6篇 |
排序方式: 共有4963条查询结果,搜索用时 15 毫秒
101.
Kenji Yano Yasuhiko Fukuda Ryo Sumimoto Kazuo Sumimoto Hisao Ito Kiyohiko Dohi 《Transplant international》1994,7(3):149-156
In this experiment, the effect of the administration route-the hepatic artery, portal vein, or systemic circulation-of the immunosuppressive drug 15-deoxyspergualin (DSG) on the suppression of liver allograft rejection is investigated. A 3-day injection of DSG at a dose of 0.32–1.28 mg/kg per day into the systemic circulation of a rat that had received a liver transplant was not effective in prolonging liver graft survival (14.3±2.9 days vs. 14.1±2.5 days for controls). However, the administration of DSG into the portal vein following liver transplantation markedly prolonged survival for up to 24.9±10.0 days. Survival times were prolonged even more when the DSG was administered via the hepatic artery for 3 successive days after liver grafting (30.9±9.6 days). The concentration of DSG in the blood following the one-shot injection of DSG was highest when DSG was administered via the hepatic artery, intermediate when injected into the portal vein, and lowest when injected into the systemic vein. In conclusion, DSG can inhibit liver graft rejection more effectively via the hepatic arterial route than via the portal vein or systemic circulation. 相似文献
102.
Junzo Shimizu Yukimitsu Kawaura Yasuhiko Tatsuzawa Kazuya Maeda Makoto Oda Atsuhiro Kawashima 《Surgery today》1999,29(9):945-947
Desmoid tumors of the chest wall following chest surgery are a rare occurrence. A case of this disease is reported herein
together with a review of the literature. A 74-year-old man, who had previously undergone a right lower lobectomy for squamous
cell carcinoma of the lung, was referred to our hospital with an abnormal shadow on his chest X-ray. The tumor, located in
the right lateral chest wall, was successfully resected by an aggressive, wide extirpation, and a final diagnosis of a desmoid
tumor originating in the chest wall was made. When following up patients after surgery for lung cancer, the possibility of
desmoid tumors developing in the incised chest wall should therefore be kept in mind. 相似文献
103.
Applicability of the Milan Criteria for Determining Liver Transplantation as a First-Line Treatment for Hepatocellular Carcinoma 总被引:1,自引:0,他引:1
Morioka D Tanaka K Matsuo K Takeda K Ueda M Sugita M Nagano Y Endo I Sekido H Togo S Shimada H 《Annals of surgical oncology》2006,13(11):1500-1510
Background To determine whether or not the Milan criteria (MC) should be used to determine the applicability of liver transplantation (LT) as a first-line treatment for patients with cirrhosis with hepatocellular carcinoma (HCC) who are able to endure hepatectomy.Methods Retrospective analysis of 82 patients with cirrhosis with HCC who were treated by hepatectomy without LT at our institution between 1990 and 2003.Results Of these 82 patients, 48 met the MC. Proportional hazard regression analyses to determine the independent prognostic factors for postoperative cumulative patient and disease-free survival showed that meeting the MC is the strongest prognostic factor for both patient and disease-free survival. The cumulative patient and disease-free survival rates were 76.7% and 28.9%, respectively, at 5 years in patients who met the MC. The cumulative disease-free survival was markedly inferior to those in previously reported series of LT for HCC who met the MC, but the cumulative patient survival was comparable to those in the previously reported series. A comparison of cumulative postoperative survival between patients who met the MC and fulfilled all five factors listed below and patients who met the MC but did not fulfill any of the five factors demonstrated that the latter patients showed statistically significantly worse postoperative patient survival than the former. The five factors included: Model for End-Stage Liver Disease score <10, indocyanine green retention rate at 15 minutes <20%, absence of microscopic fibrous capsular invasion and microscopic intrahepatic metastases, and earlier grade (T1 or T2) of American Joint Committee on Cancer tumor classification.Conclusions The MC should not be used to determine the applicability of LT as a first-line treatment for patients with HCC considered able to endure hepatectomy. However, modifying MC with some clinicopathological factors could satisfy the appropriate criteria for applying LT as a first-line treatment for these patients. 相似文献
104.
Yuko Fujihara DDS ; Hiroyuki Koyama MD PhD ; Makoto Ohba PhD ; Yasuhiko Tabata DMS PharmD PhD ; Hisako Fujihara DDS PhD ; Yoshiyuki Yonehara MD PhD ; Tsuyoshi Takato MD PhD 《Wound repair and regeneration》2008,16(1):125-131
Therapeutic angiogenesis is a promising approach to treat ischemic skin flaps. We delivered basic fibroblast growth factor (bFGF) to the recipient bed of a rat dorsal skin flap by a drug delivery system with acidic gelatin hydrogel microspheres (AGHMs), and assessed augmentation of neovascularization and flap viability. An axial skin flap was elevated on the back of male Sprague–Dawley rats, and bFGF solution or bFGF-impregnated AGHMs were injected into the recipient bed. The dose of bFGF in the bFGF solution was set to 15 (Sol-15 group), 50 (Sol-50 group), or 150 μg (Sol-150 group). Correspondingly, 2 mg AGHMs were impregnated with 15 (AGHM-15 group), 50 (AGHM-50 group), or 150 μg (AGHM-150 group) bFGF. Other groups of animals received phosphate-buffered saline (Sol-Cont group) or phosphate-buffered saline-impregnated AGHMs (AGHM-Cont group) as controls. Seven days later, analyses of the area of necrosis, microangiographic findings, and histological findings in the flap were carried out. The area of necrosis in the AGHM-150 group was significantly smaller than that in the other groups. Microangiographic and histological analyses showed that neovascularization of the ischemic skin flap significantly increased in the AGHM-150 group as compared with the Sol-150 group and the AGHM-Cont group. These findings suggest that continuous delivery of bFGF to the recipient bed by bFGF-impregnated AGHMs enhances the viability of an ischemic skin flap. 相似文献
105.
106.
Tsutomu Takeuchi Jun Koide Osamu Hosono Koichi Amano Mitsuo Homma Yasuhiko Masuho Chikao Morimoto Makoto Takano Tohru Abe 《Arthritis \u0026amp; Rheumatology》1986,29(10):1216-1222
Elevated production of anti-DNA antibody in patients with systemic lupus erythematosus (SLE) is a central problem in the pathogenesis of tissue injury. In the present study, we attempted to manipulate anti-DNA antibody production through the antigen-cytotoxic drug conjugates, DNA-daunorubicin complexes. The effect of DNA-daunorubicin complexes was determined by examining SLE lymphocytes for spontaneous in vitro production of anti-DNA antibody. These complexes, at 2 μg/ml, suppressed anti-DNA antibody production, but not total IgG production, which suggests that specific suppression of anti-DNA antibody production was achieved at this concentration. We believe that the DNA-daunorubicin complexes affected mainly B cells, since such suppression was obtained by treating B cells, as well as B plus T cells. Furthermore, the complexes had no effect on the proliferative responses of SLE T cells to DNA, phytohemagglutinin, or concanavalin A. These results indicate that DNA-daunorubicin complexes may have the potential for selectively suppressing anti-DNA antibody production in patients with SLE. 相似文献
107.
Purpose
Tongue movement with unstable swallowing cause artifacts on magnetic resonance imaging (MRI). This may be associated with loss of occlusal support. This study aimed to clarify whether motion artifacts can be mitigated by denture wearing during MRI examination in patients without occlusal support, and whether denture wearing affect tongue stability, form, and position were also evaluated.Methods
Ten subjects without occlusal support (6 male, 4 female; mean age 73.20 ± 10.12 years) participated in the study. MRI was performed with dentures worn (DW), followed with removal of dentures (NDW). Luminance standard deviation (LSD) was measured in regions of interest in the axial and sagittal planes. The position of the base of the tongue (TB), tip of the tongue apex (TA), and tongue's long diameter (TLD) were compared between DW and NDW.Results
NDW evoked ambiguous MR images in the axial and sagittal planes compared with DW. There were significant differences in LSD between DW and NDW in both the axial (p = 0.047) and sagittal planes (p = 0.02). No significant difference in the position of TB were observed (p = 0.78). The position of TA was significantly more protruded with DW (p = 0.007). Also, TLD was significantly longer with DW (p = 0.001).Conclusions
Results of this study suggest that wearing the dentures during MRI examination reduces motion artifacts in edentulous patients without occlusal support, and maintained the normal form of the tongue during imaging. 相似文献108.
Rapid reduction in BCR‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients 下载免费PDF全文
Kazunori Murai Kohei Yamaguchi Shigeki Ito Takuto Miyagishima Motohiro Shindo Kentaro Wakasa Mitsue Inomata Takahiro Nagashima Takeshi Kondo Nozomu Fujimoto Satoshi Yamamoto Masakatsu Yonezumi Tatsuo Oyake Shugo Kowata Yasuhiko Tsukushi Takahiro Mine Kuniaki Meguro Kazuhiko Ikeda Reiko Watanabe Souichi Saito Shinji Sato Katsushi Tajima Takaaki Chou Kohmei Kubo Koji Oba Junichi Sakamoto Yoji Ishida The Inter‐Michinoku Dasatinib Study Group 《European journal of haematology》2018,100(1):27-35
109.
110.
Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy 总被引:5,自引:0,他引:5
Shimizu A Horikoshi S Rinnno H Kobata M Saito K Tomino Y 《Journal of clinical laboratory analysis》2003,17(5):164-167
We determined the relationship between levels of serum cystatin C or serum creatinine (s-Cr) and prognostic stages of type 2 diabetic nephropathy. Serum samples from 174 patients with type 2 diabetes were obtained from Juntendo University Hospital, Tokyo and Juntendo Urayasu Hospital, Chiba, Japan. They were classified into four groups according to the Report of the Ministry of Health and Welfare of Japan as follows: Stage I (normoalbuminuric stage), Stage II (microalbuminuric stage), Stage IIIA (macroalbuminuric stage without renal dysfunction), Stage IIIB (macroalbuminuric stage with renal dysfunction), and Stage IV (renal failure stage). Among these patients, 68 were Stage I, 29 Stage II, 32 Stage IIIA, 17 Stage IIIB, and 28 Stage IV. The levels of serum cystatin C were measured using the Dade Behring Cystatin C assay with automated Dade Behring Nephelometer II (BNII) (Dade Behring Marburg GmbH, Germany). The mean levels of serum cystatin C in Stage IIIA were significantly higher than those in Stage I or II (P<0.00001, P<0.0005, respectively). The mean levels of serum cystatin C in Stage IIIB and Stage IV were also significantly higher than those in Stage I (P<0.00001). However, the mean levels of serum creatinine (s-Cr) in Stage IIIA were not significantly higher than those in Stage I or II. The levels of s-Cr in Stage IIIB and Stage IV were significantly higher than those in Stage I (P<0.00001). Receiver operating characteristic (ROC) plots demonstrated that the area under the curve (AUC) of cystatin C (0.76) was greater than that of s-Cr (0.66). As an early prognostic marker of type 2 diabetic nephropathy, serum cystatin C was better than s-Cr in terms of sensitivity and specificity. It appears that the levels of serum cystatin C may predict early prognostic stages of patients with type 2 diabetic nephropathy. 相似文献